

Cipla invests €15 M in Ethis for developing mRNA-based therapies

30 December 2022 | News

Initiating a strategic collaboration



Pharma major Cipla has announced that its wholly owned UK subsidiary, Cipla (EU) has signed definitive agreements for equity investment of EUR 15 million in German firm Ethis GmbH, a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

The investment will facilitate a long-term strategic partnership between Cipla and Ethis for the development of messenger RNA (mRNA)-based therapies and fast-track Cipla's participation in the mRNA space, enabling it to provide access to cutting-edge solutions developed by Ethis for the developing countries.

A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethis' innovative portfolio in Cipla's key emerging markets.

The transaction is expected to get completed within 60 days from the date of signing of the agreement or such other time-period as may be mutually agreed between the parties in writing and shall be subject to completion of necessary regulatory formalities.

Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla said, "This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients. We expect mRNA-based therapies to be one of the key innovation levers for Cipla. This inhaled mRNA technology is a paradigm shift in the delivery mechanism and this partnership reinforces Cipla's strength in respiratory therapy in line with our aspiration of attaining global lung leadership."